Truist raised the firm’s price target on Elevance Health to $600 from $580 and keeps a Buy rating on the shares after its Q1 earnings beat. The company reported better medical benefit ratio and solid cash flow, while the management also raised its guidance, the analyst tells investors in a research note. The firm adds that it is encouraged by the expanding opportunity at CarelonRx and views the CD&R partnership as a “meaningful step forward”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Elevance Health reports Medical membership totaled ~46.2M at March 31
- Elevance Health raises FY24 adjusted EPS view to greater than $37.20 per share
- Elevance Health reports Q1 adjusted EPS $10.64, consensus $10.53
- Notable companies reporting before tomorrow’s open
